Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 22, 2003

View Archived Issues

Atrix and Elan terminate pain management joint venture

Evidence of antitumor efficacy for SRL-712 and IL-2 in advanced melanoma

Fast track designation awarded to Advexin for head & neck cancer

Improved endothelial function following one year of genistein in postmenopausal women

Potential role for acetylcholinesterase inhibitors in neurogenic orthostatic hypotension

Clinical benefits of topical PTH(1-34) cream in chronic plaque psoriasis

Atorvastatin improves walking distance in patients with peripheral artery disease

Potential of liposteroids in the treatment of hemophagocytic syndrome related to SLE

Investigational HIV prime-boost vaccination evaluated in phase I trial

Dow and Sunol collaborate on plant-based production of antibody for cancer

CytRx to form Araios subsidiary with focus on obesity and type 2 diabetes

Keryx enters first SOAR collaboration for KRX-101

SBIR grant awarded for clinical trials of rhLF for diabetic foot ulcers

Eisai submits E.U. Pariet application for on-demand therapy of symptomatic GERD

Six-month priority review granted for Eloxatin sNDA

R&D progress at Celltech Group

New muscarinic M3 antagonists for use in asthma, COPD, etc.

Kv1.5 potassium channel blockers presented by BMS and ICAgen

Bayer scientists prepare and test novel anticytomegalovirus compounds

Novel benzamidine-based factor Xa inhibitors in Morphochem pipeline

Axon patent covers new aripiprazole analogues for schizophrenia and other uses

Novel PTP inhibitors in early development at Applied Research Systems

RWJ-442831, a new water-soluble prodrug of an anti-MRSA cephalosporin

Anti-MRSA carbapenems obtained by Korean scientists

GSK investigates prodrug strategies for delivery of new NNRTIs

Popular Stories

Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
AA meeting of minds as PTC, Novartis push votoplam in HD
BioWorld
What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...
Innervation can slow, as well as speed, tumor growth, study finds
BioWorld
Innervation by the sympathetic nervous system is typically a boon to tumors. But researchers from Weill Cornell Medicine and colleagues have shown that in some...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.